Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

Go back to Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
(NASDAQ: BBIO) Delayed: 67.74 --0 (-0%)
Previous Close $67.74    52 Week High $ 
Open $67.74    52 Week Low $ 
Day High $67.74    P/E N/A 
Day Low $67.74    EPS $ 
Volume 8